BOIRF:OTC-Boiron SA (USD)

COMMON STOCK | Drug Manufacturers-Specialty & Generic | OTC

Last Closing Price

USD 44.50

Change

0.00 (0.00)%

Market Cap

USD 0.78B

Avg Analyst Target

N/A

Avg User Target

USD
Average Analyst Rating

N/A

Fundamental Analysis

Verdict


Boiron SA (BOIRF) Stock Analysis:
Based on the Boiron SA stock forecasts from 0 analysts, the average analyst target price for Boiron SA is not available over the next 12 months. Boiron SA’s average analyst rating is not available. Stock Target Advisor’s own stock analysis of Boiron SA is Neutral, which is based on 6 positive signals and 6 negative signals. At the last closing, Boiron SA’s stock price was USD 44.50. Boiron SA’s stock price has changed by +0.00% over the past week, +0.00% over the past month and +1.37% over the last year.

No recent analyst target price found for Boiron SA
No recent average analyst rating found for Boiron SA

About

Boiron SA manufactures and sells homeopathic medicines in France, rest of Europe, North America, and internationally. The company offers non-proprietary, proprietary, branded homeopathic medicines. Its branded homeopathic medicines include Oscillococcinum to treat flu like sympto ...Read More

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2022-01-23 )

Largest Industry Peers for Drug Manufacturers-Specialty & Generic

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
MKKGY MERCK Kommanditgesellschaft au..

N/A

USD96.17B 30.49 21.63
MKGAF MERCK Kommanditgesellschaft au..

N/A

USD95.72B 31.08 21.63
TKPHF Takeda Pharmaceutical Company ..

N/A

USD45.89B 11.17 0.06
SGIOY Shionogi & Co. Ltd

N/A

USD18.78B 18.71 0.12
SGIOF Shionogi & Co. Ltd

N/A

USD18.40B 18.34 0.12
SFOSF Shanghai Fosun Pharmaceutical ..

N/A

USD17.87B 16.05 3.03
ESALF Eisai Co. Ltd

N/A

USD15.43B 28.08 0.13
ESALY Eisai Co. Ltd

N/A

USD14.92B 27.14 0.13
GNHAF Vifor Pharma AG

N/A

USD11.39B 24.45 12.99
MTZPY Mitsubishi Tanabe Pharma Corpo..

N/A

USD10.43B 79.00 0.21

ETFs Containing BOIRF

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Drug Manufacturers-Specialty & Generic)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Trailing 12 Months  
Capital Gain 1.37% 80% B- 54% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 1.37% 79% C+ 51% F
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain -10.50% 25% F 10% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -10.50% 25% F 9% F
Risk Return Profile  
Volatility (Standard Deviation) 27.34% 92% A- 71% C-
Risk Adjusted Return -38.41% 21% F 10% F
Market Capitalization 0.78B 86% B 64% D
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Drug Manufacturers-Specialty & Generic)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 38.97 16% F 17% F
Price/Book Ratio 1.40 57% F 55% F
Price / Cash Flow Ratio 11.41 12% F 17% F
EV/EBITDA 7.92 40% F 37% F
Management Effectiveness  
Return on Equity 3.64% 73% C 46% F
Return on Invested Capital 11.45% 72% C- 74% C
Return on Assets 3.01% 82% B- 69% D+
Debt to Equity Ratio 0.65% 66% D 79% C+
Technical Ratios  
Short Ratio N/A N/A N/A N/A N/A
Short Percent N/A N/A N/A N/A N/A
Beta 0.70 61% D- 58% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date

No discussions yet

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector